- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01784536
Open Label Study Evaluating the Effects of a Single Oritavancin Infusion on Cytochrome P450 in Healthy Volunteers (DDI)
December 13, 2023 updated by: Melinta Therapeutics, Inc.
Study Evaluating the Effects of a Single Oritavancin Infusion on Cytochrome P450 (CYP) 1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A, N-Acetyltransferase-2, and Xanthine Oxidase Activities in Healthy Adults Using the Cooperstown 5 + 1 Cocktail
The purpose of this study is to examine the effects of oritavancin on the in vivo activities of CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A, NAT 2, and XO using a Cooperstown 5 + 1 cocktail in an open label, single arm manner.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
16
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Wisconsin
-
West Bend, Wisconsin, United States, 53095
- Spaulding Clinical
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Provides written informed consent before study initiation.
- Healthy male or female adult between 18 and 45 years of age, inclusive.
- Body mass index (BMI) between 18 and 32 kg/m^2, inclusive.
- Nonsmoker for a 6-month period before Screening.
- In good health based upon results of medical history, physical examination, no clinically significant 12-lead ECG results, and laboratory test results.
- Agrees to avoid all medications (other than the study drugs) that may inhibit or induce hepatic microsomal enzymes during the study period, including prescription and nonprescription medications, vitamins, herbal supplements (including energy drinks), and nutraceuticals.
- Female subject is surgically sterile, postmenopausal, or, if of childbearing potential, agrees to use an acceptable nonhormonal method of contraception during all study phases.
- Agree to abstain from alcohol, caffeine-, and xanthine-containing products, all kind of energy drinks and the consumption of grapefruit juice and orange juice from 48 hours before study drug administration until completion of the follow-up visit.
Exclusion Criteria:
- Has acute or chronic respiratory disease.
- The use of nonprescription drugs during the 30-day period before screening.
- The use of any prescription drugs during the 3-month period before.
- Childbearing potential, a positive test result for urine or serum, human chorionic gonadotropin (hCG) at Screening.
- Positive serology result for hepatitis B surface antigen, hepatitis C virus antibody, or has known hepatitis B or C infection at screening.
- Positive serology result for human immunodeficiency virus (HIV) or has known immune deficiency disease at Screening.
- Requires anticoagulant monitoring with an activated partial thromboplastin time.
- Has an elevated international normalized ratio >1.3.
- Surgical or medical condition that could interfere with the administration of the study drug.
- Any condition that may affect drug absorption.
- Has a known intolerance to benzodiazepines, the active and/or inactive ingredients in caffeine, warfarin, vitamin K, omeprazole, or dextromethorphan.
- The use of any nicotine containing substance or nicotine replacement devices within 6 months before Screening.
- Has received an immunization during the 2-week period before screening.
- Has hemorrhagic tendencies or blood dyscrasias.
- Has poor venous access as determined by the investigator.
- Reports regular alcohol intake exceeding 1 drink/day within 1 month before screening.
- A poor metabolizer (based on medical history, if known) of CYP2D6, CYP2C9, or CYP2C19.
- Has participated in other clinical research studies involving the evaluation of other investigational drugs or devices within 30 days before enrollment.
- Excluded for any of the previous criteria may not be rescreened for participation at any time.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Oritavancin
Single-Dose IV Oritavancin Diphosphate
|
Oritavancin will be administered as a single IV infusion.
The infusion will last approximately 3 hours.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in the phenotyping measures of each probe drug in the absence and presence of oritavancin
Time Frame: Day 1 through Day 5
|
Day 1 through Day 5
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety of probe drug administration and prolonged infusion of oritavancin as assessed by AEs/SAEs, clinical safety laboratory results, vital sign measurements, 12 lead ECG results, and physical examination findings
Time Frame: Day 1 through Day 28
|
Day 1 through Day 28
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Carlos Sanabria, MD, Spaulding Clinical
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2013
Primary Completion (Actual)
March 1, 2013
Study Completion (Actual)
March 1, 2013
Study Registration Dates
First Submitted
February 4, 2013
First Submitted That Met QC Criteria
February 4, 2013
First Posted (Estimated)
February 6, 2013
Study Record Updates
Last Update Posted (Actual)
December 19, 2023
Last Update Submitted That Met QC Criteria
December 13, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MDCO-ORI-12-03
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Single-Dose IV Oritavancin Diphosphate
-
Melinta Therapeutics, Inc.Completed
-
Melinta Therapeutics, Inc.Completed
-
Melinta Therapeutics, Inc.CompletedAbscess | Cellulitis | Wound Infection | Systemic InflammationUnited States
-
Melinta Therapeutics, Inc.CompletedAbscess | Cellulitis | Wound Infection | Systemic InflammationUnited States
-
AblynxCompletedHealthy VolunteersUnited States
-
GlaxoSmithKlineCompletedAsthmaUnited Kingdom
-
Rockefeller UniversityBrigham and Women's Hospital; Weill Medical College of Cornell University; University...CompletedHealthy | HIVUnited States, Germany
-
GlaxoSmithKlineCompletedRespiratory DisordersUnited Kingdom
-
Rockefeller UniversityUniversity of CologneCompletedHealthy | HIVGermany, United States
-
PfizerCompletedFungal InfectionNetherlands